Compare Boston Scientific Corp. with Similar Stocks
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.61%
0%
-23.61%
6 Months
-29.3%
0%
-29.3%
1 Year
-27.08%
0%
-27.08%
2 Years
17.29%
0%
17.29%
3 Years
55.67%
0%
55.67%
4 Years
76.53%
0%
76.53%
5 Years
94.79%
0%
94.79%
Boston Scientific Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
12.73%
EBIT Growth (5y)
26.06%
EBIT to Interest (avg)
5.69
Debt to EBITDA (avg)
2.84
Net Debt to Equity (avg)
0.47
Sales to Capital Employed (avg)
0.51
Tax Ratio
18.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
92.93%
ROCE (avg)
6.99%
ROE (avg)
7.79%
Valuation key factors
Factor
Value
P/E Ratio
86
Industry P/E
Price to Book Value
8.01
EV to EBIT
64.79
EV to EBITDA
44.86
EV to Capital Employed
5.78
EV to Sales
10.73
PEG Ratio
6.37
Dividend Yield
5843.20%
ROCE (Latest)
8.92%
ROE (Latest)
9.28%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot : Sep 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 190 Schemes (36.18%)
Foreign Institutions
Held by 582 Foreign Institutions (22.3%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
5,061.00
4,663.00
8.54%
Operating Profit (PBDIT) excl Other Income
1,258.00
1,221.00
3.03%
Interest
99.00
87.00
13.79%
Exceptional Items
-256.00
-57.00
-349.12%
Consolidate Net Profit
795.00
672.00
18.30%
Operating Profit Margin (Excl OI)
182.20%
192.20%
-1.00%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 8.54% vs 2.24% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 18.30% vs 19.57% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
16,747.00
14,240.00
17.61%
Operating Profit (PBDIT) excl Other Income
3,904.00
3,377.00
15.61%
Interest
387.00
272.00
42.28%
Exceptional Items
-32.00
-71.00
54.93%
Consolidate Net Profit
1,846.00
1,592.00
15.95%
Operating Profit Margin (Excl OI)
157.30%
153.20%
0.41%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 17.61% vs 12.29% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 15.95% vs 128.08% in Dec 2023
About Boston Scientific Corp. 
Boston Scientific Corp.
Retailing
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Company Coordinates 
Company Details
300 BOSTON SCIENTIFIC WAY , MARLBOROUGH MA : 01752-1234
Registrar Details






